Compare GSK plc (GSK) vs Raytheon Technologies Corp (RTX) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

RTX trades at $193.39, down 1.53% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding the $1.51 estimate. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award (PRNewsWire, June 3, 2026), highlight defense sector strength.

Outlook remains positive with analyst consensus price target of $213.00 (69% buy ratings), though elevated P/E of 36.28 poses valuation risk. Key opportunities include defense spending tailwinds and margin expansion, while risks involve debt levels and geopolitical volatility affecting contracts.